Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium effects on lung hyperinflation and dyspnea in COPD
NCT00274027Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2001
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Tiotropium with Placebo (2 arms). Primary endpoint: Borg dyspnea rating at a standardized exercise time up to 7 weeks. Started Jan 2001; status: completed.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00274027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274027.